| Dr Mark Edward Fechtel, OD | |
|
16968 W Bell Rd Ste 402, Surprise, AZ 85374-8943 | |
| (623) 214-0353 | |
| (623) 214-0693 |
| Full Name | Dr Mark Edward Fechtel |
|---|---|
| Gender | Male |
| Speciality | Optometrist |
| Location | 16968 W Bell Rd Ste 402, Surprise, Arizona |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356338636 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 1117 (Arizona) | Primary |
| Provider Name | Active Eyecare Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1295100204 PECOS PAC ID: 8426316993 Enrollment ID: O20171212000108 |
News Archive
Amgen announced today results from Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES), a Phase 3 trial which evaluated Neulasta (pegfilgrastim) in 845 patients receiving FOLFOX or FOLFIRI and bevacizumab for the first-line treatment of locally-advanced or metastatic colorectal cancer.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the favorable efficacy profile of Roche's MabThera (rituximab) is the most significant driver of their use of this brand, while 26 percent say MabThera's favorable risk-benefit profile is the most significant driver.
Many patients with ulcerative colitis don't receive recommended testing and treatment for the common problem of iron deficiency anemia, reports a study in the October issue of Inflammatory Bowel Diseases, official journal of the Crohn's & Colitis Foundation of America (CCFA). The journal is published by Wolters Kluwer.
Ending one of the longest-running disputes left by Hurricane Katrina, a federal arbitration panel ruled Wednesday that Louisiana would receive $474.8 million — nearly all it had requested — to pay for the replacement of Charity Hospital in New Orleans, which has been closed since the storm.
Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mark Edward Fechtel, OD 220 N Mckemy Ave, Chandler, AZ 85226-2654 Ph: (480) 961-1865 | Dr Mark Edward Fechtel, OD 16968 W Bell Rd Ste 402, Surprise, AZ 85374-8943 Ph: (623) 214-0353 |
News Archive
Amgen announced today results from Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES), a Phase 3 trial which evaluated Neulasta (pegfilgrastim) in 845 patients receiving FOLFOX or FOLFIRI and bevacizumab for the first-line treatment of locally-advanced or metastatic colorectal cancer.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the favorable efficacy profile of Roche's MabThera (rituximab) is the most significant driver of their use of this brand, while 26 percent say MabThera's favorable risk-benefit profile is the most significant driver.
Many patients with ulcerative colitis don't receive recommended testing and treatment for the common problem of iron deficiency anemia, reports a study in the October issue of Inflammatory Bowel Diseases, official journal of the Crohn's & Colitis Foundation of America (CCFA). The journal is published by Wolters Kluwer.
Ending one of the longest-running disputes left by Hurricane Katrina, a federal arbitration panel ruled Wednesday that Louisiana would receive $474.8 million — nearly all it had requested — to pay for the replacement of Charity Hospital in New Orleans, which has been closed since the storm.
Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.
› Verified 4 days ago
Jesse Austin Lam, OD Optometrist Medicare: Medicare Enrolled Practice Location: 13371 W Grand Ave Ste 102, Surprise, AZ 85374 Phone: 623-556-8083 | |
Eyemasters Optometrist Medicare: Not Enrolled in Medicare Practice Location: 13371 W Grand Ave, Ste. 102, Surprise, AZ 85374 Phone: 623-556-8038 | |
Dr. Sara Beth Ornstein, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 15033 W Bell Rd, Suite 150, Surprise, AZ 85374 Phone: 623-533-4697 Fax: 623-533-4907 | |
Daniel David Ziemann, OD Optometrist Medicare: Medicare Enrolled Practice Location: 13641 N Prasada Pkwy Ste 100, Surprise, AZ 85388 Phone: 623-401-1275 | |
Tom Sowash O.d. & Associates, P.c. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 13641 N Prasada Pkwy Ste 100, Surprise, AZ 85388 Phone: 726-444-4545 | |
Joseph Myers, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 12361 W Bola Dr Ste 100, Surprise, AZ 85378 Phone: 602-767-4124 Fax: 602-767-4125 | |
Dr. Paige Renae Blom, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 16860 W Waddell Rd Ste 102, Surprise, AZ 85388 Phone: 602-643-4054 |